Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up-Reference-Cited by-同舟云学术

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up

Published:2024-06-28 Issue:1 Volume:14 Page:83-95
ISSN:2411-4634
Container-title:Head and Neck Tumors (HNT)
language:
Short-container-title:Opuholi golovy i šei

Author:

Shurinov A. Yu.¹^ORCID,Borodavina E. V.¹^ORCID,Krylov V. V.¹,Sigov M. A.¹^ORCID,Rodichev A. A.¹^ORCID,Ivanov S. A.²^ORCID,Kaprin A. D.³^ORCID

Affiliation:

1. A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Center of Radiology, Ministry of Health of Russia

2. A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Center of Radiology, Ministry of Health of Russia; Peoples’ Friendship University of Russia

3. Peoples’ Friendship University of Russia; National Medical Research Radiological Center, Ministry of Health of Russia; P.A. Herzen Moscow Oncology Research Institute — a branch of the National Medical Radiology Research Center, Ministry of Health of Russia

Abstract

The radioiodine therapy is a one of the basic elements at combined treatment of differentiated thyroid cancer and is an alternative method for patients with distant metastases and a potentially high risk of tumor recurrence. It has been used in clinical practice for more than 80 years. The first report on the phenomenon of accumulation of 130I/131I in a metastatic focus of differentiated thyroid cancer was published by A. Keston et al. in 1942, and in 1946, the production of 131I was established, and the drug became available. In our country, radioiodine therapy has been widely used for the treatment of differentiated thyroid cancer since 1982.This article presents methodological recommendations for radioiodine therapy of patients with differentiated thyroid cancer, provides a modern examination algorithm, discusses the basic principles of laboratory, instrumental diagnostics and treatment approaches treatment of this disease.

Publisher

Publishing House ABV Press

Reference25 articles.

1. Choinzonov E.L., Reshetov I.V., Ivanov S.A. et al. Draft clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients. Endokrinnaya khirurgiya = Endocrine Surgery 2022;16(2):5-29. (In Russ.). DOI: 10.14341/serg12792

2. Shishkina V.V., Chebotareva E.D., Semichev D.S. Therapeutic use of open radionuclides. Kiev, 1988. Pp. 4—10. (In Russ.).

3. Filetti S., Bidart J., Arturi F. et al. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999;141(5):443-57. DOI: 10.1530/eje.0.1410443

4. Bogolyubova A.V., Abrosimov A.Yu., Selivanova L.S., Belousov P.V. Histological and molecular genetic characteristics of clinically aggressive variants of papillary thyroid cancer. Arkhiv patologii = Pathology Archive 2019;81(1):46-51. (In Russ.). DOI: 10.17116/patol20198101146

5. Tuttle R., Ahuja S., Avram A. et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 2019;29(4):461-70. DOI: 10.1089/thy.2018.0597

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness;Head and Neck Tumors (HNT);2024-08-04